Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy combined with conventional therapies is being broadly applied in non-small cell lung cancer (NSCLC) patients. However, the risk of interstitial pneumonitis (IP) following a combined regimen is incompletely characterized. METHODS: A total of 46,12...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xue-Jun, Cai, Xiao-Ting, Rong, Zi-Xuan, Zhang, Yan-Pei, Wen, Yu-Xiang, Bai, Xue, Wang, Jian, Fu, Qiang John, Guo, Ze-Qin, Long, Li-Li, Ma, Si-Cong, Tang, Xin-Ran, Liu, Li, Guan, Jian, Dong, Zhong-Yi, Wu, De-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814324/
https://www.ncbi.nlm.nih.gov/pubmed/36600276
http://dx.doi.org/10.1186/s12916-022-02713-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814324/
https://www.ncbi.nlm.nih.gov/pubmed/36600276
http://dx.doi.org/10.1186/s12916-022-02713-6

Ejemplares similares